Premyelinating Oligodendrocytes in Chronic Lesions of Multiple Sclerosis
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Background Multiple sclerosis is an inflammatory disease of the central nervous system that destroys myelin, oligodendrocytes, and axons. Since most of the lesions of multiple sclerosis are not remyelinated, enhancement of remyelination is a possible therapeutic strategy that could perhaps be achieved with the transplantation of oligodendrocyte-producing cells into the lesions. We investigated the frequency distribution and configuration of oligodendrocytes in chronic lesions of multiple sclerosis to determine whether these factors limit remyelination. Methods Forty-eight chronic lesions obtained at autopsy from 10 patients with multiple sclerosis were examined immunocytochemically for oligodendrocytes and oligodendrocyte progenitor cells. Using confocal microscopy, we examined the three-dimensional relations between axons and the processes of premyelinating oligodendrocytes. Results Thirty-four of the 48 chronic lesions of multiple sclerosis contained oligodendrocytes with multiple extended processes that associated with demyelinated axons but failed to myelinate them. These axons were dystrophic and contained multiple swellings. In some regions, the densities of premyelinating oligodendrocytes (25 per square millimeter of tissue) were similar to those in the developing rodent brain (23 per square millimeter). In the patients with disease of long duration (more than 20 years), there were fewer lesions with premyelinating oligodendrocytes (P Conclusions Premyelinating oligode…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The efficacy of remyelination has been shown to depend on multiple factors such as, age, disease duration and lesion location.”
From BCAS1-positive oligodendrocytes enable efficient cortical remyelination in multiple sclerosis (2025) · cites this paper as [12]
In the citing paper
“The long‐term consequence of demyelination in the CNS is axonal damage and neurodegeneration (Chang et al. 2002) in both white and gray matter lesions, leading to progressive disease.”
From Depletion of Microglia Increases Cortical Oligodendrocyte Density During Remyelination (2026) · cites this paper as Chang et al. 2002
In the citing paper
“In MS lesions, OPCs are recruited but fail to differentiate into myelinating OLs, suggesting that remyelination is blocked at the differentiation and remyelination stage rather than during OPC recruitment (Chang et al., 2002; Kuhlmann et al., 2008; Wolswijk, 1998).”
From miR-219 Cooperates with miR-338 in Myelination and Promotes Myelin Repair in the CNS (2017) · cites this paper as Chang et al., 2002
In the citing paper
“In MS lesions, OPCs are recruited but fail to differentiate into myelinating OLs, suggesting that remyelination is blocked at the differentiation and remyelination stage rather than during OPC recruitment (Chang et al., 2002; Kuhlmann et al., 2008; Wolswijk, 1998).”
From miR-219 Cooperates with miR-338 in Myelination and Promotes Myelin Repair in the CNS (2017) · cites this paper as Chang et al., 2002
In the citing paper
“Furthermore, oligodendrocyte progenitor cells (OPCs) are a population of adult stem cells responsible for mediating CNS myelin repair in demyelinating conditions such as MS [113,114].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [114]
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Self-citationNoseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
Raff, M. C., Miller, R. H., & Noble, M. (1983) · Nature · doi:10.1038/303390a0 · Cited by 2,030
Axonal damage in acute multiple sclerosis lesions
Ferguson, B. (1997) · Brain · doi:10.1093/brain/120.3.393 · Cited by 1,532
WEINSHENKER, B. G., BASS, B., RICE, G. P. A., NOSEWORTHY, J., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C. (1989) · Brain · doi:10.1093/brain/112.1.133 · Cited by 1,452
Cell death and control of cell survival in the oligodendrocyte lineage
Barres, B. A., Hart, I. K., Coles, H. S. R., Burne, J. F., Voyvodic, J. T., Richardson, W. D., & Raff, M. C. (1992) · Cell · doi:10.1016/0092-8674(92)90531-g · Cited by 1,345
Multiple Sclerosis and Chronic Autoimmune Encephalomyelitis
Kornek, B., Storch, M. K., Weissert, R., Wallstroem, E., Stefferl, A., Olsson, T., Linington, C., Schmidbauer, M., & Lassmann, H. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64537-3 · Cited by 921
The oligodendrocyte and its many cellular processes
PFEIFFER, S., WARRINGTON, A., & BANSAL, R. (1993) · Trends in Cell Biology · doi:10.1016/0962-8924(93)90213-k · Cited by 737
NG2-Positive Oligodendrocyte Progenitor Cells in Adult Human Brain and Multiple Sclerosis Lesions
Chang, A., Nishiyama, A., Peterson, J., Prineas, J., & Trapp, B. D. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-17-06404.2000 · Cited by 712
Self-citation
Research works printed but not linked: 2
- 10.1056/nejm199801293380610 · doi:10.1056/nejm199801293380610 · Paper page
- Prineas JW, 1989, Lab Invest, 61, 489
Cited by
Compston, A., & Coles, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61620-7 · Cited by 4,372
Compston, A., & Coles, A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08220-x · Cited by 1,743
Remyelination in the CNS: from biology to therapy
Franklin, R. J. M., & ffrench-Constant, C. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2480 · Cited by 1,544
Progressive multiple sclerosis: pathology and pathogenesis
Lassmann, H., van Horssen, J., & Mahad, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.168 · Cited by 1,033
Lassmann, H. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a028936 · Cited by 937
Oligodendrocytes: biology and pathology
Bradl, M., & Lassmann, H. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0601-5 · Cited by 933
Polydendrocytes (NG2 cells): multifunctional cells with lineage plasticity
Nishiyama, A., Komitova, M., Suzuki, R., & Zhu, X. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2495 · Cited by 865
Kuhlmann, T., Miron, V., Cuo, Q., Wegner, C., Antel, J., & Bruck, W. (2008) · Brain · doi:10.1093/brain/awn096 · Cited by 864
“However, recent publications indicate that the number of OPCs is reduced over time in multiple sclerosis lesions (Chang et al., 2002; Reynolds et al., 2002; Wolswijk 2002; Wilson et al., 2006).”
BackgroundResultWhy does remyelination fail in multiple sclerosis?
Franklin, R. J. M. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn917 · Cited by 837
“cgi?l=5354">PLP )-expressing pre-myelinating oligodendrocytes that have progressed to the stage of engaging demyelinated axons but have not progressed further to form compacted myelin sheath”
BackgroundRemyelination is extensive in a subset of multiple sclerosis patients
Patrikios, P., Stadelmann, C., Kutzelnigg, A., Rauschka, H., Schmidbauer, M., Laursen, H., Sorensen, P. S., Bruck, W., Lucchinetti, C., & Lassmann, H. (2006) · Brain · doi:10.1093/brain/awl217 · Cited by 807
“In some lesions, however, progenitor cells are abundantly present (Chang et al., 2000; Chang et al., 2002), but they may fail either because the axons are not permissive for remyelination (Charles et al., 2002) or the maturation of progenitor cells is inhibited (John et al., 2002).”
BackgroundMyelin in the Central Nervous System: Structure, Function, and Pathology
Stadelmann, C., Timmler, S., Barrantes-Freer, A., & Simons, M. (2019) · Physiological Reviews · doi:10.1152/physrev.00031.2018 · Cited by 728
“In agreement with the notion that the ability to remyelinate may not be restricted to early stages of lesion formation, premyelinating and actively myelinating oligodendrocytes can be visualized around chronic MS lesions (109, 175) (FIGURE 7).”
BackgroundDevelopmental genetics of vertebrate glial–cell specification
Rowitch, D. H., & Kriegstein, A. R. (2010) · Nature · doi:10.1038/nature09611 · Cited by 715
“For example, in multiple sclerosis and periventricular leukomalacia, markers (such as OLIG2) identified in developmental studies have been examined in neuropathological studies, showing that OPCs are blocked in their differentiation and fail to carry out normal repair functions after white-matter injur”
BackgroundMyelin Impairs CNS Remyelination by Inhibiting Oligodendrocyte Precursor Cell Differentiation
Kotter, M. R., Li, W.-W., Zhao, C., & Franklin, R. J. M. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2615-05.2006 · Cited by 768
“However, for unknown reasons, the process may become arrested at the differentiation/ maturation phase, leaving lesions containing oligodendrocyte lineage cells but chronically demyelinated and vulnerable to progressive axonal degeneration (Wolswijk, 1998;Chang et al., 2000, 2002).”
BackgroundDysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS
Fancy, S. P. J., Baranzini, S. E., Zhao, C., Yuk, D.-I., Irvine, K.-A., Kaing, S., Sanai, N., Franklin, R. J. M., & Rowitch, D. H. (2009) · Genes & Development · doi:10.1101/gad.1806309 · Cited by 618
“The finding of OLPs and premyelinating oligodendrocytes in chronic lesions of MS suggest that remyelination is most vulnerable during their differentiation rather than their recruitment (Wolswijk 1998; Chang et al. 2002; Kuhlmann et al. 2008).”
BackgroundMultiple sclerosis progression: time for a new mechanism-driven framework
Kuhlmann, T., Moccia, M., Coetzee, T., Cohen, J. A., Correale, J., Graves, J., Marrie, R. A., Montalban, X., Yong, V. W., Thompson, A. J., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00289-7 · Cited by 667
Role of the innate and adaptive immune responses in the course of multiple sclerosis
Hemmer, B., Kerschensteiner, M., & Korn, T. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70305-9 · Cited by 584
Oligodendrocytes in development, myelin generation and beyond
Kuhn, S., Gritti, L., Crooks, D., & Dombrowski, Y. (2019) · Cells · doi:10.3390/cells8111424 · Cited by 625
“identified a block in OPC differentiation into oligodendrocytes as the bottleneck for efficient remyelination in MS [225,226].”
BackgroundHyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation
Back, S. A., Tuohy, T. M. F., Chen, H., Wallingford, N., Craig, A., Struve, J., Luo, N. L., Banine, F., Liu, Y., Chang, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1279 · Cited by 612
Self-citationNew concepts in the immunopathogenesis of multiple sclerosis
Hemmer, B., Archelos, J. J., & Hartung, H.-P. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn784 · Cited by 580
“These findings indicate that active oligodendrocytes might still be present even in chronic lesions, but do not succeed in remyelinating axon”
Retinoid X receptor gamma signaling accelerates CNS remyelination
Huang, J. K., Jarjour, A. A., Nait Oumesmar, B., Kerninon, C., Williams, A., Krezel, W., Kagechika, H., Bauer, J., Zhao, C., Evercooren, A. B.-V., et al. (2011) · Nature Neuroscience · doi:10.1038/nn.2702 · Cited by 547
“, owing in part to the failure of adult OPCs to differentiate into myelinating oligodendrocyte”
Myelin remodeling through experience-dependent oligodendrogenesis in the adult somatosensory cortex
Hughes, E. G., Orthmann-Murphy, J. L., Langseth, A. J., & Bergles, D. E. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0121-5 · Cited by 540
“Analysis of demyelinated areas in brain tissue from human MS patients revealed a high incidence of oligodendrocytes with a premyelinating morphology 44 , suggesting that the process of oligodendrocyte maturation may be stalled.”
A regenerative approach to the treatment of multiple sclerosis
Deshmukh, V. A., Tardif, V., Lyssiotis, C. A., Green, C. C., Kerman, B., Kim, H. J., Padmanabhan, K., Swoboda, J. G., Ahmad, I., Kondo, T., et al. (2013) · Nature · doi:10.1038/nature12647 · Cited by 531
Choi, I. Y., Piccio, L., Childress, P., Bollman, B., Ghosh, A., Brandhorst, S., Suarez, J., Michalsen, A., Cross, A. H., Morgan, T. E., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.009 · Cited by 505
“Although oligodendrocyte precursor cells (OPCs) can migrate to the sites of MS lesions, they often fail to differentiate into functional oligodendrocytes (Chang et al., 2002; Wolswijk, 1998).”
Rapid production of new oligodendrocytes is required in the earliest stages of motor-skill learning
Xiao, L., Ohayon, D., McKenzie, I. A., Sinclair-Wilson, A., Wright, J. L., Fudge, A. D., Emery, B., Li, H., & Richardson, W. D. (2016) · Nature Neuroscience · doi:10.1038/nn.4351 · Cited by 507
Shen, S., Sandoval, J., Swiss, V. A., Li, J., Dupree, J., Franklin, R. J. M., & Casaccia-Bonnefil, P. (2008) · Nature Neuroscience · doi:10.1038/nn.2172 · Cited by 481
“Inefficient OPC differentiation in aging mirrors non-remyelinating plaques in humans with multiple sclerosis, which are replete with oligodendrocyte-lineage cells that fail to differentiate into remyelinating oligodendrocyte”
The cuprizone animal model: new insights into an old story
Kipp, M., Clarner, T., Dang, J., Copray, S., & Beyer, C. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0591-3 · Cited by 481
“Therefore, remyelination seems not to be limited by an absence of OPC or their failure to generate oligodendrocytes [18, 78].”
BackgroundJohn, G. R., Shankar, S. L., Shafit-Zagardo, B., Massimi, A., Lee, S. C., Raine, C. S., & Brosnan, C. F. (2002) · Nature Medicine · doi:10.1038/nm781 · Cited by 477
“It is now well accepted that MS lesions contain substantial numbers of premyelinating oligodendrocytes, indicating that the potential for repair is not limited by the loss of these cell”
BackgroundIntracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration
Bø, L., Vedeler, C. A., Nyland, H., Trapp, B. D., & Mørk, S. J. (2003) · Multiple Sclerosis Journal · doi:10.1191/1352458503ms917oa · Cited by 478
Self-citationMetformin restores CNS remyelination capacity by rejuvenating aged stem cells
Neumann, B., Baror, R., Zhao, C., Segel, M., Dietmann, S., Rawji, K. S., Foerster, S., McClain, C. R., Chalut, K., van Wijngaarden, P., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.08.015 · Cited by 449
“Chronically demyelinated MS lesions either lack OPCs or, more commonly, contain OPCs that have failed to differentiate (Boyd et al., 2013; Chang et al., 2002; Kuhlmann et al., 2008).”
BackgroundAgeing, Cellular Senescence and Neurodegenerative Disease
Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448
“Furthermore, oligodendrocyte progenitor cells (OPCs) are a population of adult stem cells responsible for mediating CNS myelin repair in demyelinating conditions such as MS [113,114].”
BackgroundRemyelination in multiple sclerosis
Piaton, G., Williams, A., Seilhean, D., & Lubetzki, C. (2009) · Progress in Brain Research · doi:10.1016/s0079-6123(09)17530-1 · Cited by 441
Oligodendrocyte-Encoded HIF Function Couples Postnatal Myelination and White Matter Angiogenesis
Yuen, T. J., Silbereis, J. C., Griveau, A., Chang, S. M., Daneman, R., Fancy, S. P. J., Zahed, H., Maltepe, E., & Rowitch, D. H. (2014) · Cell · doi:10.1016/j.cell.2014.04.052 · Cited by 433
Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo
Najm, F. J., Madhavan, M., Zaremba, A., Shick, E., Karl, R. T., Factor, D. C., Miller, T. E., Nevin, Z. S., Kantor, C., Sargent, A., et al. (2015) · Nature · doi:10.1038/nature14335 · Cited by 424
bHLH Transcription Factor Olig1 Is Required to Repair Demyelinated Lesions in the CNS
Arnett, H. A., Fancy, S. P. J., Alberta, J. A., Zhao, C., Plant, S. R., Kaing, S., Raine, C. S., Rowitch, D. H., Franklin, R. J. M., & Stiles, C. D. (2004) · Science · doi:10.1126/science.1103709 · Cited by 416
Kirby, B. B., Takada, N., Latimer, A. J., Shin, J., Carney, T. J., Kelsh, R. N., & Appel, B. (2006) · Nature Neuroscience · doi:10.1038/nn1803 · Cited by 404
Remyelination capacity of the MS brain decreases with disease chronicity
Goldschmidt, T., Antel, J., König, F. B., Brück, W., & Kuhlmann, T. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a8260a · Cited by 411
Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis
Cohen, J. A., & Chun, J. (2011) · Annals of Neurology · doi:10.1002/ana.22426 · Cited by 393
Dynamics of oligodendrocyte generation in multiple sclerosis
Yeung, M. S. Y., Djelloul, M., Steiner, E., Bernard, S., Salehpour, M., Possnert, G., Brundin, L., & Frisén, J. (2019) · Nature · doi:10.1038/s41586-018-0842-3 · Cited by 376
Olig2 Targets Chromatin Remodelers to Enhancers to Initiate Oligodendrocyte Differentiation
Yu, Y., Chen, Y., Kim, B., Wang, H., Zhao, C., He, X., Liu, L., Liu, W., Wu, L. M. N., Mao, M., et al. (2013) · Cell · doi:10.1016/j.cell.2012.12.006 · Cited by 375
Hyaluronan blocks oligodendrocyte progenitor maturation and remyelination through TLR2
Sloane, J. A., Batt, C., Ma, Y., Harris, Z. M., Trapp, B., & Vartanian, T. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006496107 · Cited by 360
Self-citationRemyelination in multiple sclerosis: From basic science to clinical translation
Lubetzki, C., Zalc, B., Williams, A., Stadelmann, C., & Stankoff, B. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30140-x · Cited by 350
Axin2 as regulatory and therapeutic target in newborn brain injury and remyelination
Fancy, S. P. J., Harrington, E. P., Yuen, T. J., Silbereis, J. C., Zhao, C., Baranzini, S. E., Bruce, C. C., Otero, J. J., Huang, E. J., Nusse, R., et al. (2011) · Nature Neuroscience · doi:10.1038/nn.2855 · Cited by 349
“Conversely, inhibition of remyelination may contribute to ongoing neurological dysfunction, axonal loss and disease progressio”
BackgroundChen, Y., Wu, H., Wang, S., Koito, H., Li, J., Ye, F., Hoang, J., Escobar, S. S., Gow, A., Arnett, H. A., et al. (2009) · Nature Neuroscience · doi:10.1038/nn.2410 · Cited by 346
“A common feature of demyelinated lesions is the differentiation block of oligodendrocyte precursors at a pre-myelinating stage 36, 37.”
Self-citationEdg8/S1P5: An Oligodendroglial Receptor with Dual Function on Process Retraction and Cell Survival
Jaillard, C., Harrison, S., Stankoff, B., Aigrot, M. S., Calver, A. R., Duddy, G., Walsh, F. S., Pangalos, M. N., Arimura, N., Kaibuchi, K., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4645-04.2005 · Cited by 338
Myelin Regeneration: A Recapitulation of Development?
Fancy, S. P. J., Chan, J. R., Baranzini, S. E., Franklin, R. J. M., & Rowitch, D. H. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113629 · Cited by 320
Woodruff, R. H., Fruttiger, M., Richardson, W. D., & Franklin, R. J. M. (2004) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2003.10.014 · Cited by 335
“Several recent studies suggest that this might be a problem because long-term demyelinated lesions can be found that contain OPCs and premyelinating oligodendrocytes that are apparently unable to differentiate further (Chang et al., 2000, 2002; Wolswijk, 1998).”
BackgroundActivation of the subventricular zone in multiple sclerosis: Evidence for early glial progenitors
Nait-Oumesmar, B., Picard-Riera, N., Kerninon, C., Decker, L., Seilhean, D., Höglinger, G. U., Hirsch, E. C., Reynolds, R., & Baron-Van Evercooren, A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606835104 · Cited by 322
Remyelinated Lesions in Multiple Sclerosis: Magnetic Resonance Image Appearance
Barkhof, F., Brück, W., De Groot, C. J. A., Bergers, E., Hulshof, S., Geurts, J., Polman, C. H., & van der Valk, P. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1073 · Cited by 328
“Remyelination relies on the presence of oligodendrocytes that either survive the demyelinating attack or that are recruited from a progenitor pool; both conditions have been observed in MS lesions,(11-14) although recent data suggest that remyelination of denuded axons may fail frequently.(15) The MRI appearance of re…”
BackgroundPersistent 7-tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions
Absinta, M., Sati, P., Schindler, M., Leibovitch, E. C., Ohayon, J., Wu, T., Meani, A., Filippi, M., Jacobson, S., Cortese, I. C. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86198 · Cited by 327
“Reasons for remyelination failure may include impaired oligodendrocyte precursor differentiation and maturation (3), axo-glial interaction (4), energy homeostasis, and clearance of cytotoxic inflammation (5–8).”
BackgroundRemyelination can be extensive in multiple sclerosis despite a long disease course
Patani, R., Balaratnam, M., Vora, A., & Reynolds, R. (2007) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2007.00805.x · Cited by 318
Mei, F., Lehmann-Horn, K., Shen, Y.-A. A., Rankin, K. A., Stebbins, K. J., Lorrain, D. S., Pekarek, K., A Sagan, S., Xiao, L., Teuscher, C., et al. (2016) · eLife · doi:10.7554/elife.18246 · Cited by 321
“Remyelination is an inefficient process in MS, which is likely due to an inhibitory microenvironment that prevents oligodendrocyte precursor cells (OPCs) from terminally differentiating into myelinating oligodendrocytes (Chang et al., 2002; Huang and Franklin, 2011; Kuhlmann et al., 2008; Wolswijk, 1998).”
BackgroundOligodendrocyte development and the onset of myelination in the human fetal brain
Jakovcevski, I. (2009) · Frontiers in Neuroanatomy · doi:10.3389/neuro.05.005.2009 · Cited by 323
“…lack of functional remyelination in the MS plaques may be due to specifi c inhibition of oligodendrocyte differentiation, despite the fact that oligodendrocyte precursors are present in and around the lesions (Chang et al., 2002; Filipovic et al., 2002; Levine et al., 2001; Scolding et al., 1998).”
BackgroundInfluentialPathology of multiple sclerosis and related inflammatory demyelinating diseases
(2014) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-52001-2.00002-9 · Cited by 303
Extensive cortical remyelination in patients with chronic multiple sclerosis
Albert, M., Antel, J., Brück, W., & Stadelmann, C. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2006.00043.x · Cited by 314
“Recently, the presence of abundant “premyelinating oligodendrocytes” in MS lesions and their inability to remyelinate these lesions have been documented (12).”
BackgroundThe molecular basis of neurodegeneration in multiple sclerosis
Lassmann, H., & van Horssen, J. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.08.004 · Cited by 294
“Remyelination may occur, but in the majority of the patients it is impaired [87], even when oligodendrocyte progenitor cells are present [16].”
BackgroundMolecular Control of Oligodendrocyte Development
Elbaz, B., & Popko, B. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2019.01.002 · Cited by 293
“Nevertheless, the brains of MS patients with remyelination failure are characterized by the presence of oligodendrocytes at the pre-myelinating stage in the vicinity of demyelinated axons [8].”
BackgroundMi, S., Miller, R. H., Tang, W., Lee, X., Hu, B., Wu, W., Zhang, Y., Shields, C. B., Zhang, Y., Miklasz, S., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21581 · Cited by 300
“In MS plaques, premyelinating oligodendrocytes are observed near demyelinated axons, suggesting the presence of environmental inhibitors to the repair process.(5) Although in a chronic MS lesion there is substantial axonal loss that is unlikely to be reversed by inhibiting LINGO-1, it appears likely that the promotion…”
BackgroundProgressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function
Ontaneda, D., Thompson, A. J., Fox, R. J., & Cohen, J. A. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31320-4 · Cited by 298
Boyd, A., Zhang, H., & Williams, A. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1112-y · Cited by 287
“Molecules affecting other processes necessary for remyelination, such as migration, have been less studied in spite of a third of demyelinated MS plaques containing few OPCs [6, 27].”
BackgroundRemyelination therapies: a new direction and challenge in multiple sclerosis
Plemel, J. R., Liu, W.-Q., & Yong, V. W. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.115 · Cited by 281
In Vivo Magnetic Resonance Tracking of Magnetically Labeled Cells after Transplantation
Bulte, J. W. M., Duncan, I. D., & Frank, J. A. (2002) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200208000-00001 · Cited by 288
“Although recent studies suggest that significant numbers of oligodendrocyte progenitors can be present in and around MS lesions (Chang et al., 2002; Wolswijk, 2002), eventual remyelination is not complete, and other means of promoting repair are required to restore function in affected patients.”
ResultNeuroprotection and repair in multiple sclerosis
Franklin, R. J. M., ffrench-Constant, C., Edgar, J. M., & Smith, K. J. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.200 · Cited by 278
Burt, R. K., Loh, Y., Cohen, B., Stefosky, D., Balabanov, R., Katsamakis, G., Oyama, Y., Russell, E. J., Stern, J., Muraro, P., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70017-1 · Cited by 282
Remyelination in Experimental Models of Toxin-Induced Demyelination
Blakemore, W. F., & Franklin, R. J. M. (2008) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-540-73677-6_8 · Cited by 275
“This hypothesis provides an explanation why OPCs and premyelinating oligodendrocytes can reside adjacent to demyelinated axons without remyelination occurring [27, 28 , 36, 96, 97] .”
BackgroundKerschensteiner, M., Stadelmann, C., Dechant, G., Wekerle, H., & Hohlfeld, R. (2003) · Annals of Neurology · doi:10.1002/ana.10446 · Cited by 273
“This may prove particularly interesting in light of recent findings suggesting that many premyelinating oligodendrocytes survive but fail to remyelinate in chronic MS lesions.(80) Finally, neurotrophins, particularly NGF, act as immunomodulators, interacting with local microglia as well as invading immune cells.”
BackgroundBennett, J., Basivireddy, J., Kollar, A., Biron, K. E., Reickmann, P., Jefferies, W. A., & McQuaid, S. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.08.011 · Cited by 265
“…remyelination may reflect persistent BBB permeability-mediated astrogliosis, leading to inhibition of access by oligodendrocyte precursors (OPCs) to demyelinated axons rather than absolute deficiency of OPC in late stage lesions (Chang et al., 2002; Faulkner and Keirstead, 2005; Keirstead, 2005).”
BackgroundMyelinogenesis and Axonal Recognition by Oligodendrocytes in Brain Are Uncoupled in Olig1-Null Mice
Xin, M., Yue, T., Ma, Z., Wu, F.-F., Gow, A., & Lu, Q. R. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3034-04.2005 · Cited by 255
“This presents a particular challenge for myelin repair in demyelinating diseases, in which OPCs are present within lesions but fail to form myelinating oligodendrocytes (Chang et al., 2002).”
BackgroundInhibition of Myelin Membrane Sheath Formation by Oligodendrocyte-derived Exosome-like Vesicles
Bakhti, M., Winter, C., & Simons, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.190009 · Cited by 253
Larsen, P. H., Wells, J. E., Stallcup, W. B., Opdenakker, G., & Yong, V. W. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-35-11127.2003 · Cited by 260
“The CNS does attempt recovery from such insults, and remyelination occurs in MS lesions, albeit to a limited extent (Prineas et al., 1993; Chang et al., 2002).”
BackgroundMechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis
Zivadinov, R., Reder, A. T., Filippi, M., Minagar, A., Stüve, O., Lassmann, H., Racke, M. K., Dwyer, M. G., Frohman, E. M., & Khan, O. (2008) · Neurology · doi:10.1212/01.wnl.0000316810.01120.05 · Cited by 260
Benito, C., Romero, J. P., Tolón, R. M., Clemente, D., Docagne, F., Hillard, C. J., Guaza, C., & Romero, J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4814-06.2007 · Cited by 256
“…staining of MS lesions with anti-myelin antibodies to estimate lesion age is widely accepted (Bruck et al., 1995; Noseworthy et al., 2000; Chang et al., 2002; van der Goes et al., 2005), these data provide evidence that the induction of CB2 receptor expression in plaqueassociated…”
BackgroundChondroitin sulfate proteoglycans in demyelinated lesions impair remyelination
Lau, L. W., Keough, M. B., Haylock‐Jacobs, S., Cua, R., Döring, A., Sloka, S., Stirling, D. P., Rivest, S., & Yong, V. W. (2012) · Annals of Neurology · doi:10.1002/ana.23599 · Cited by 245
Cells of the oligodendroglial lineage, myelination, and remyelination
Miron, V. E., Kuhlmann, T., & Antel, J. P. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.09.010 · Cited by 242
“The aforementioned importance of inflammation in inducing the activation of OPCs and resultant remyelination would also suggest that OPCs in un-remyelinated MS lesions may still be functional yet are not immersed in the appropriate inflammatory environment that would induce differentiation [135,139].”
Fard, M. K., van der Meer, F., Sánchez, P., Cantuti-Castelvetri, L., Mandad, S., Jäkel, S., Fornasiero, E. F., Schmitt, S., Ehrlich, M., Starost, L., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aam7816 · Cited by 249
“PLP is one of the major structural proteins in myelin and therefore not only highly expressed in mature myelin-forming oligodendrocytes but also present in premyelinating cells during development (24).”
BackgroundDynamic Imaging of Individual Remyelination Profiles in Multiple Sclerosis
Bodini, B., Veronese, M., García‐Lorenzo, D., Battaglini, M., Poirion, E., Chardain, A., Freeman, L., Louapre, C., Tchikviladze, M., Papeix, C., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24620 · Cited by 240
“40 However, the Although no significant correlation was found between the index of dynamic demyelination and EDSS, a strong inverse correlation was found between the index of dynamic remyelination and EDSS.”
BackgroundNiu, J., Tsai, H.-H., Hoi, K. K., Huang, N., Yu, G., Kim, K., Baranzini, S. E., Xiao, L., Chan, J. R., & Fancy, S. P. J. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0369-4 · Cited by 237
Oxidative stress and its impact on neurons and glia in multiple sclerosis lesions
Lassmann, H., & van Horssen, J. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.09.018 · Cited by 238
Pusic, A. D., & Kraig, R. P. (2014) · Glia · doi:10.1002/glia.22606 · Cited by 242
“, 2003), and abundant OPCs have been observed in the absence of remyelination in advanced MS lesions (Chang et al., 2002).”
BackgroundSemaphorin 3A and 3F: key players in myelin repair in multiple sclerosis?
Williams, A., Piaton, G., Aigrot, M.-S., Belhadi, A., Theaudin, M., Petermann, F., Thomas, J.-L., Zalc, B., & Lubetzki, C. (2007) · Brain · doi:10.1093/brain/awm202 · Cited by 227
“Recent data have demonstrated that such oligodendrocyte precursor cells persist in the adult murine brain, as well as in normal human and MS brain (Chang et al., 2002; Reynolds et al., 2002; Wilson et al., 2006).”
BackgroundProgesterone Synthesis in the Nervous System: Implications for Myelination and Myelin Repair
Schumacher, M., Hussain, R., Gago, N., Oudinet, J.-P., Mattern, C., & Ghoumari, A. M. (2012) · Frontiers in Neuroscience · doi:10.3389/fnins.2012.00010 · Cited by 217
“This process, named “remyelination” or “myelin repair,” requires the generation of new oligodendrocytes from oligodendrocyte progenitor cells (OPC; Chang et al., 2002; Franklin and FFrench-Constant, 2008).”
BackgroundGlial Development: The Crossroads of Regeneration and Repair in the CNS
Gallo, V., & Deneen, B. (2014) · Neuron · doi:10.1016/j.neuron.2014.06.010 · Cited by 220
Inflammation stimulates remyelination in areas of chronic demyelination
Foote, A. K. (2005) · Brain · doi:10.1093/brain/awh417 · Cited by 230
“…environment such as pertains in areas of chronic demyelination, where oligodendrocyte progenitor cells (OPCs) with the potential for remyelination may be present but fail to achieve remyelination (Wolswijk, 1998; Chang et al., 2000, 2002), has been hampered by a lack of suitable models.”
BackgroundResultInfluentialNicaise, A. M., Wagstaff, L. J., Willis, C. M., Paisie, C., Chandok, H., Robson, P., Fossati, V., Williams, A., & Crocker, S. J. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818348116 · Cited by 233
Modulating CCR2 and CCL2 at the blood–brain barrier: relevance for multiple sclerosis pathogenesis
Mahad, D., Callahan, M. K., Williams, K. A., Ubogu, E. E., Kivisäkk, P., Tucky, B., Kidd, G., Kingsbury, G. A., Chang, A., Fox, R. J., et al. (2006) · Brain · doi:10.1093/brain/awh655 · Cited by 223
“Autopsy and surgical resection material from CNS pathologies Autopsy material from multiple sclerosis cases was collected at the Netherlands Brain Bank and the Cleveland Clinic Foundation according to their respective rapid autopsy protocols (Ravid and Swaab, 1993; Chang et al., 2002).”
MethodSelf-citationNatrajan, M. S., de la Fuente, A. G., Crawford, A. H., Linehan, E., Nuñez, V., Johnson, K. R., Wu, T., Fitzgerald, D. C., Ricote, M., Bielekova, B., et al. (2015) · Brain · doi:10.1093/brain/awv289 · Cited by 218
Quantifying the early stages of remyelination following cuprizone-induced demyelination
Stidworthy, M. F., Genoud, S., Suter, U., Mantei, N., & Franklin, R. J. M. (2003) · Brain Pathology · doi:10.1111/j.1750-3639.2003.tb00032.x · Cited by 224
“Introduction There is accumulating evidence to suggest that a subset of chronically demyelinated lesions in multiple sclerosis contain oligodendrocyte progenitors which fail to differentiate into myelin sheath forming cells (8, 9, 26, 27).”
BackgroundOlig gene function in CNS development and disease
Ligon, K. L., Fancy, S. P. J., Franklin, R. J. M., & Rowitch, D. H. (2006) · Glia · doi:10.1002/glia.20273 · Cited by 223
“…instances remyelination failure is due to a blockade of OLP differentiation, with lesions containing many oligodendrocyte lineage cells that fail to differentiate fully into remyelinating oligodendrocytes (Scolding et al., 1998; Wolswijk, 1998; Chang et al., 2000, 2002; Franklin and Goldman, 2004).”
BackgroundIntracellular signaling pathway regulation of myelination and remyelination in the CNS
Gaesser, J. M., & Fyffe-Maricich, S. L. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.03.008 · Cited by 210
“…that apply to the journal pertain. anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript disorders including cerebral palsy (CP) and multiple sclerosis (MS) reflect the loss of myelinating OLs (Chang et al., 2002; Franklin, 2002; Khwaja and Volpe, 2008; Woodward et al., 2006).”
BackgroundGlia Disease and Repair—Remyelination
Franklin, R. J. M., & Goldman, S. A. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020594 · Cited by 208
“2000), PLP (to reveal premyelinating oligodendrocytes) (Chang et al. 2002), and Olig2 and Nkx2.”
BackgroundCortical remyelination: A new target for repair therapies in multiple sclerosis
Chang, A., Staugaitis, S. M., Dutta, R., Batt, C. E., Easley, K. E., Chomyk, A. M., Yong, V. W., Fox, R. J., Kidd, G. J., & Trapp, B. D. (2012) · Annals of Neurology · doi:10.1002/ana.23693 · Cited by 216
“limited by reduced recruitment of oligodendrocyte progenitor cells, failure of oligodendrocyte progenitor cells to generate oligodendrocytes, and failure of oligodendrocytes to differentiate into myelin-forming cells.(17,21,22) These limitations could be regulated by a variety of cellular and environmental factors, in…”
BackgroundMethodSelf-citationSimpson, J. E., Fernando, M. S., Clark, L., Ince, P. G., Matthews, F., Forster, G., O'Brien, J. T., Barber, R., Kalaria, R. N., Brayne, C., et al. (2007) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2007.00828.x · Cited by 215
Mason, J. L., Toews, A., Hostettler, J. D., Morell, P., Suzuki, K., Goldman, J. E., & Matsushima, G. K. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63726-1 · Cited by 212
“Although the central nervous system (CNS) has the ability to regenerate new oligodendrocytes that remyelinate demyelinated axons following acute demyelination, it has been suggested that mature oligodendrocytes are not regenerated within chronically demyelinated lesions due to: 1) the depletion of the oligodendrocyte…”
BackgroundThe pathology of multiple sclerosis
Lucchinetti, C. F., Parisi, J., & Bruck, W. (2005) · Neurologic Clinics · doi:10.1016/j.ncl.2004.09.002 · Cited by 208
Astrocyte-derived endothelin-1 inhibits remyelination through notch activation
Hammond, T. R., Gadea, A., Dupree, J., Kerninon, C., Nait-Oumesmar, B., Aguirre, A., & Gallo, V. (2014) · Neuron · doi:10.1016/j.neuron.2013.11.015 · Cited by 206
“However, several studies have shown that OPCs often fail to differentiate in chronic MS lesions (Chang et al., 2002; Wolswijk, 1998).”
BackgroundInflammatory demyelinating diseases of the central nervous system
(2018) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-802395-2.00019-5 · Cited by 188
“…in a considerable number of patients has been attributed to a failure of OPC differentiation, which may be influenced by age and hormones (Chang et al., 2002; Chari et al., 2003; Kotter et al., 2011), loss of axons in the lesions (Charles et al., 2002), and the loss of macrophages in the…”
Remyelination in multiple sclerosis
Brück, W., Kuhlmann, T., & Stadelmann, C. (2003) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00191-0 · Cited by 200
“There may be either a lack of the right sequence of growth factor stimulation that is necessary for the development of oligodendrocytes [37], an impaired axon–oligodendrocyte interaction, or the glial scar that hinders remyelination [29].”
BackgroundLysolecithin induces demyelination in vitro in a cerebellar slice culture system
Birgbauer, E., Rao, T. S., & Webb, M. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20248 · Cited by 188
“Other studies, however, have found significant numbers of OPCs around MS lesions, although they seem to have failed to differentiate into mature oligodendrocytes (Wolswijk, 2000; Chang et al., 2002), and thus failure to remyelinate in MS may be due to a failure to induce differentiation of oligodendrocytes.”
BackgroundResultOvercoming remyelination failure in multiple sclerosis and other myelin disorders
Fancy, S. P. J., Kotter, M. R., Harrington, E. P., Huang, J. K., Zhao, C., Rowitch, D. H., & Franklin, R. J. M. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.12.020 · Cited by 192
“…mirrors and may be in part a determinant of a now well-recognised feature of many chronically demyelinated MS lesions that are replete with oligodendrocyte lineage cells that fail to differentiate into myelinating oligodendrocytes (Chang et al., 2002; Kuhlmann et al., 2008; Wolswijk, 1998).”
BackgroundNemes-Baran, A. D., White, D. R., & DeSilva, T. M. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108047 · Cited by 196
“Studies of human post-mortem brains from individuals afflicted with multiple sclerosis show that pre-myelinating OLs are present in chronic lesions of multiple sclerosis but do not form myelin (Chang et al., 2002).”
BackgroundMechanisms of white matter damage in multiple sclerosis
Lassmann, H. (2014) · Glia · doi:10.1002/glia.22597 · Cited by 191
“…as loss of axons in the lesions or their unresponsiveness for remyelination (Charles et al., 2002), blockade of OPC migration and differentiation (Chang et al., 2002, Williams et al., 2007b, Kuhlmann et al., 2009, Bramow et al., 2010), or the loss of macrophages and 1822 Volume 62, No.…”
Background
Metadata
- Authors
- Chang, A., Tourtellotte, W. W., Rudick, R., & Trapp, B. D.
- Affiliations
- Cleveland Clinic (US)
- VA West Los Angeles Medical Center (US)
- Cleveland Clinic Research (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-01-17
- Volume
- 346
- Issue
- 3
- Pages
- 165-173
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2058358434
- Cited by
- 991
- References
- 39
- Citations by year
- 2026: 19 · 2025: 25 · 2024: 42 · 2023: 38 · 2022: 32 · 2021: 34 · 2020: 36 · 2019: 57 · 2018: 43 · 2017: 52 · 2016: 44 · 2015: 55 · 2014: 44 · 2013: 50 · 2012: 40
- FWCI
- 26.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Neurological Disorders and Stroke (R01 NS35058, P01NS038667, R01NS035058, P01-NS-38667)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Keywords
- multiple sclerosis, remyelination, chronic lesions, demyelinated axons, oligodendrocyte precursor cells, disease duration
- MeSH terms
- Chondroitin Sulfate Proteoglycan 4, Adult, Aged, Antigens, Axons, Brain, Brain Chemistry, Female, Humans, Male, Middle Aged, Multiple Sclerosis, Nerve Fibers, Myelinated, Oligodendroglia, Proteoglycans, Stem Cells, Microscopy, Confocal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.